Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene

• DOI: 10.1096/fj.99-1010fje
• Publication Date: 2002-07-26T23:03:10Z
• Authors: José-A. Silva; Ronaldo C. Araujo; Ovidiu Baltatu; Suzana M. Oliveira; Carsten Tschöpe; Edwin Fink; Sigrid Hoffmann; Ralph Plehm; Karl X. Chai; Lee Chao; Julie Chao; Detlev Ganten; João B. Pesquero; Michael Bader
• Keywords: 0301 basic medicine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiomegaly; Kinins; Fibrosis; Rats; 3. Good health; Animals, Genetically Modified; 03 medical and health sciences; Animals; Humans; Kallikreins

To evaluate the cardiovascular actions of kinins, we established a transgenic rat line harboring the human tissue kallikrein gene, TGR(hKLK1). Under the control of the zinc-inducible metallothionein promoter, the transgene was expressed in most tissues including the heart, kidney, lung, and brain, and human kallikrein was detected in the urine of transgenic animals. Transgenic rats had a lower 24-h mean arterial pressure in comparison with control rats, which was further decreased when their diet was supplemented with zinc. The day/night rhythm of blood pressure was significantly diminished in TGR(hKLK1) animals, whereas the circadian rhythms of heart rate and locomotor activity were unaffected. Induction of cardiac hypertrophy by isoproterenol treatment revealed a marked protective effect of the kallikrein transgene because the cardiac weight of TGR(hKLK1) increased significantly less, and the expression of atrial natriuretic peptide and collagen III as markers for hypertrophy and fibrosis, respectively, were less enhanced. The specific kinin-B2 receptor antagonist, icatibant, abolished this cardioprotective effect. In conclusion, the kallikrein-kinin system is an important determinant in the regulation of blood pressure and its circadian rhythmicity. It also exerts antihypertrophic and antifibrotic actions in the heart.